bloodjourГематология и трансфузиологияRussian journal of hematology and transfusiology0234-57302411-3042ООО Издательский дом «Практика»10.18821/0234-5730-2016-61-2-65-72bloodjour-42Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESКлинико-гематологическая гетерогенность острых миелоидных лейкозов и миелодиспластических синдромов с моносомным кариотипомClinico-haematological heterogeneity of acute myeloid leukemias and myelodysplastic syndromes with monosomal karyotypehttps://orcid.org/0000-0003-3768-0831КостромаИ. И.KostromaI. I.

Кострома Иван Иванович, младший научный сотрудник клинического отдела «Гематология»

193024, г. Санкт-Петербург

Kostroma Ivan I., junior researcher of the Department of Hematology

St.Petersburg, 193024

obex@rambler.ruhttps://orcid.org/0000-0001-7586-4709ГрицаевС. В.GritsaevS. V.

193024, г. Санкт-Петербург

St.Petersburg, 193024

https://orcid.org/0000-0001-5958-0490МартынкевичИ. С.MartynkevichI. S.

193024, г. Санкт-Петербург

St.Petersburg, 193024

https://orcid.org/0000-0002-3888-7407ЧубукинаЖ. В.ChubukinaZh. V.

193024, г. Санкт-Петербург

St.Petersburg, 193024

https://orcid.org/0000-0003-1428-3059МартыненкоЛ. С.MartynenkoL. S.

193024, г. Санкт-Петербург

St.Petersburg, 193024

https://orcid.org/0000-0001-5450-2944ИвановаМ. П.IvanovaM. P.

193024, г. Санкт-Петербург

St.Petersburg, 193024

https://orcid.org/0000-0002-2919-1459ТирановаС. А.TiranovaS. A.

193024, г. Санкт-Петербург

St.Petersburg, 193024

https://orcid.org/0000-0002-9445-7452ПотихоноваН. А.PotikhonovaN. A.

193024, г. Санкт-Петербург

St.Petersburg, 193024

https://orcid.org/000-0002-3771-909XАбдулкадыровК. М.AbdulkadyrovK. M.

193024, г. Санкт-Петербург

St.Petersburg, 193024

ФГБУ «Российский научно-исследовательский институт гематологии и трансфузиологии» ФМБА РоссииРоссияRussian Research Institute of Hematology and TransfusiologyRussian Federation2016280220196126572Copyright © Кострома И.И., Грицаев С.В., Мартынкевич И.С., Чубукина Ж.В., Мартыненко Л.С., Иванова М.П., Тиранова С.А., Потихонова Н.А., Абдулкадыров К.М., 20192019Кострома И.И., Грицаев С.В., Мартынкевич И.С., Чубукина Ж.В., Мартыненко Л.С., Иванова М.П., Тиранова С.А., Потихонова Н.А., Абдулкадыров К.М.Kostroma I.I., Gritsaev S.V., Martynkevich I.S., Chubukina Z.V., Martynenko L.S., Ivanova M.P., Tiranova S.A., Potikhonova N.A., Abdulkadyrov K.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.htjournal.ru/jour/article/view/42

Моносомный кариотип – крайне неблагоприятный вариант хромосомных аберраций у больных острыми миелоидными лейкозами (ОМЛ) и миелодиспластическими синдромами (МДС). Для обнаружения клинических и лабораторных параметров, ассоциированных с моносомным кариотипом, проведен ретроспективный анализ данных 76 больных (43 больных ОМЛ и 33 больных МДС). Не выявлено показателей, характерных для случаев с моносомным кариотипом. Медиана общей выживаемости больных ОМЛ и МДС составила 6 и 8 мес соответственно. Вместе с тем у отдельных больных отмечено относительно благоприятное течение ОМЛ и МДС.

Monosomal karyotype is the extremely poor variant of chromosomal aberrations in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Retrospective analysis of 43 AML and 33 MDS patients was performed to determine typical clinical and hematological features of chromosomal karyotype. No characteristics typical for monosomal karyotype were found. Median of overall survival of AML and MDS patients was 6 and 8 months accordingly. At the same time some patients had relatively favorable course of their disease.

острые миелоидные лейкозымиелодиспластические синдромымоносомный кариотипacute myeloid leukemiamyelodysplastic syndromesmonosomal karyotypeReferencesСавченко В.Г., Паровичникова Е.Н., Афанасьев Б.В., Грицаев С.В., Семочкин С.В., Бондаренко С.Н. и др. Национальные клинические рекомендации по диагностике и лечению острых миелоидных лейкозов. Гематология и трансфузиология. 2014; 1: Прил. 2.Savchenko V.G., Parovichnikova E.N., Afanasiev B.V., Gritsaev S.V., Semochkin S.V., Bondarenko S.N., et al. National clinical recommendations on diagnosis and treatment of acute myeloid leukemias. Hematology and Transfusiology. Russian journal (Gematologiya i transfusiologiya). 2014; 1(Suppl. 2). (in Russian)Dohner H., Estey E.H., Amadori S., Appelbaum F.R., Buchner T., Burnett A.K. et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010; 115(3): 453–74.Dohner H., Estey E.H., Amadori S., Appelbaum F.R., Buchner T., Burnett A.K. et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010; 115(3): 453–74.Greenberg P.L., Tuechler H., Schanz J., Sanz G., Garcia-Manero G., Sole F., et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120(12): 2454–65.Greenberg P.L., Tuechler H., Schanz J., Sanz G., Garcia-Manero G., Sole F., et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120(12): 2454–65.Breems D.A., van Putten W.L., de Greef G.E., van ZelderenBhola S.L., Gerssen-Schoorl K.B., Mellink C.H., et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J. Clin. Oncol. 2008; 26(29): 4791–7.Breems D.A., van Putten W.L., de Greef G.E., van ZelderenBhola S.L., Gerssen-Schoorl K.B., Mellink C.H., et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J. Clin. Oncol. 2008; 26(29): 4791–7.Medeiros B.C., Othus M., Fang M., Roulston D., Appelbaum F.R. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood. 2010; 116(13): 2224–8.Medeiros B.C., Othus M., Fang M., Roulston D., Appelbaum F.R. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood. 2010; 116(13): 2224–8.Perrot A., Luquet I., Pigneux A., Mugneret F., Delaunay J., Harousseau J.L., et al. Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities. Blood. 2011; 118(3): 679–85.Perrot A., Luquet I., Pigneux A., Mugneret F., Delaunay J., Harousseau J.L., et al. Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities. Blood. 2011; 118(3): 679–85.Kayser S., Zucknick M., Dohner K., Krauter J., Kohne C.H., Horst H.A., et al. Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. Blood. 2012; 119(2): 551–8.Kayser S., Zucknick M., Dohner K., Krauter J., Kohne C.H., Horst H.A., et al. Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. Blood. 2012; 119(2): 551–8.Patnaik M.M., Hanson C.A., Hodnefeld J.M., Knudson R., van Dyke D.L., Tefferi A. Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype. Leukemia. 2012; 25(2): 266–70.Patnaik M.M., Hanson C.A., Hodnefeld J.M., Knudson R., van Dyke D.L., Tefferi A. Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype. Leukemia. 2012; 25(2): 266–70.Rogers H.J., Vardiman J.W., Anastasi J., Raca G., Savage N.M., Cherry A.M., et al. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3) (q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. Haematologica. 2014; 99(5): 821–9.Rogers H.J., Vardiman J.W., Anastasi J., Raca G., Savage N.M., Cherry A.M., et al. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3) (q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. Haematologica. 2014; 99(5): 821–9.Ahn H.K., Jang J.H., Kim K., Kim H.J., Kim S.H., Jung C.W., Kim D.H. Monosomal karyotype in acute myeloid leukemia predicts adverse treatment outcome and associates with high functional multidrug resistance activity. Am. J. Hematol. 2012; 87(1): 37–41.Ahn H.K., Jang J.H., Kim K., Kim H.J., Kim S.H., Jung C.W., Kim D.H. Monosomal karyotype in acute myeloid leukemia predicts adverse treatment outcome and associates with high functional multidrug resistance activity. Am. J. Hematol. 2012; 87(1): 37–41.Rucker F.G., Schlenk R.F., Bullinger L., Kayser S., Teleanu V., Kett H., et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specifc copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012; 119(9): 2114–21.Rucker F.G., Schlenk R.F., Bullinger L., Kayser S., Teleanu V., Kett H., et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specifc copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012; 119(9): 2114–21.Gaillard J.B., Chiesa J., Reboul D., Arnaud A., Brun S., Donadio D., et al. Monosomal karyotype routinely defnes a poor prognosis subgroup in acute myeloid leukemia and is frequently associated with TP53 deletion. Leuk. Lymphoma. 2012; 53(2); 336–7.Gaillard J.B., Chiesa J., Reboul D., Arnaud A., Brun S., Donadio D., et al. Monosomal karyotype routinely defnes a poor prognosis subgroup in acute myeloid leukemia and is frequently associated with TP53 deletion. Leuk. Lymphoma. 2012; 53(2); 336–7.Грицаев С.В., Мартынкевич И.С., Абдулкадыров К.М., Мартыненко Л.С., Иванова М.П., Аксенова В.Б. и др. Возрастные особенности кариотипа больных острым миелоидным лейкозом. Терапевтический архив. 2011; 1: 51–5.Gritsaev S.V., Martynkevich I.S., Abdulkadyrov K.M., Martynenko L.S., Ivanova M.P., Aksenova V.B., et al. Age-related karyotype features of patients with acute myeloid leukemia. Therapeutic archive. Russian journal (Terapevticheskiy arkhiv). 2011; 1: 51–5. (in Russian)Cornelissen J.J., Breems D., van Putten W.L.J., Gratwohl A.A., Passweg J.R., Pabst T., et al. Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. J. Clin. Oncol. 2012; 30(17): 2140–6.Cornelissen J.J., Breems D., van Putten W.L.J., Gratwohl A.A., Passweg J.R., Pabst T., et al. Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. J. Clin. Oncol. 2012; 30(17): 2140–6.Garcia J.S., Medeiros B.C., Appelbaum F.R. Blood consult: monosomal karyotype acute myeloid leukemia. Blood. 2012; 119(24): 5659–60.Garcia J.S., Medeiros B.C., Appelbaum F.R. Blood consult: monosomal karyotype acute myeloid leukemia. Blood. 2012; 119(24): 5659–60.Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., et al. The 2008 revision of the World Health Organization (WHO) classifcation of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114(5): 937–51.Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., et al. The 2008 revision of the World Health Organization (WHO) classifcation of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114(5): 937–51.Cheson B.D., Bennett J.M., Kopecky K.J., Buchner T., Willman C.L., Estey E.H., et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J. Clin. Oncol. 2003; 21(24): 4642–9.Cheson B.D., Bennett J.M., Kopecky K.J., Buchner T., Willman C.L., Estey E.H., et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J. Clin. Oncol. 2003; 21(24): 4642–9.Cheson B.D., Greenberg P.L., Bennett J.M., Lowenberg B., Wijermans P.W., Nimer S.D., et al. Clinical application and proposal for modifcation of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108(2): 419–25.Cheson B.D., Greenberg P.L., Bennett J.M., Lowenberg B., Wijermans P.W., Nimer S.D., et al. Clinical application and proposal for modifcation of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108(2): 419–25.Грицаев С.В., Мартынкевич И.С., Кострома И.И., Аксенова В.Ю., Петрова Е.В., Сергеев А.Н. и др. Децитабин: уроки, извлеченные из опыта лечения больных миелоидными неоплазиями. Клиническая онкогематология. 2012; 3: 225–31.Gritsaev S.V., Martynkevich I.S., Kostroma I.I., Aksenova V.Yu., Petrova E.V., Sergeev A.N., et al. Decitabine: lessons of clinical practice to treat the patients with myeloid neoplasms. Clinical Oncohematology. Russian journal (Klinicheskaya onkogematologiya). 2012; 3: 225–31]. (in Russian)Грицаев С.В., Мартынкевич И.С., Зюзгин И.С., Карягина Е.В., Мартыненко Л.С., Петрова Е.В. и др. Гетерогенность острого миелоидного лейкоза с транслокацией t(8;21) (q22;q22). Терапевтический архив. 2014; 7: 45–52.Gritsaev S.V., Martynkevich I.S., Zyuzgin I.S., Karyagina E.V., Martynenko L.S., Petrova E.V., et al. Heterogeneity of acute myeloid leukemia with translocation t(8;21)(q22;q22). Therapeutic archive. Russian journal (Terapevticheskiy arkhiv). 2014; 7: 45–52. (in Russian)Xing R., Li C., Gale R.P., Zhang Y., Xu Z., Qin T., et al. Monosomal karyotype is an independent predictor of survival in patients with higher-risk myelodysplastic syndrome. Am. J. Hematol. 2014; 89(10): E163–8.Xing R., Li C., Gale R.P., Zhang Y., Xu Z., Qin T., et al. Monosomal karyotype is an independent predictor of survival in patients with higher-risk myelodysplastic syndrome. Am. J. Hematol. 2014; 89(10): E163–8.Lazarevic V., Horstedt A.S., Johansson B., Antunovic P., Billstrom R., Derolf A., et al. Incidence and prognostic signifcance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience. Blood Cancer J. 2014; 4: e188. doi: 10.1038/bcj.2014.10.Lazarevic V., Horstedt A.S., Johansson B., Antunovic P., Billstrom R., Derolf A., et al. Incidence and prognostic signifcance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience. Blood Cancer J. 2014; 4: e188. doi: 10.1038/bcj.2014.10.Schanz J., Tuchler H., Sole F., Mallo M., Luno E., Cervera J., et al. Monosomal karyotype in MDS: explaining the poor prognosis? Leukemia. 2013; 27(10): 1988–95.Schanz J., Tuchler H., Sole F., Mallo M., Luno E., Cervera J., et al. Monosomal karyotype in MDS: explaining the poor prognosis? Leukemia. 2013; 27(10): 1988–95.Breems D.A., Lowenberg B. Acute myeloid leukemia with monosomal karyotype at the far end of the unfavorable prognostic spectrum. Haematologica. 2011; 96(4): 491–3.Breems D.A., Lowenberg B. Acute myeloid leukemia with monosomal karyotype at the far end of the unfavorable prognostic spectrum. Haematologica. 2011; 96(4): 491–3.Lowenberg B., Pabst T., Vellenga E., van Putten W., Schouten H.C., Graux C., et al. Cytarabine dose for acute myeloid leukemia. N. Engl. J. Med. 2011; 364(11): 1027–36.Lowenberg B., Pabst T., Vellenga E., van Putten W., Schouten H.C., Graux C., et al. Cytarabine dose for acute myeloid leukemia. N. Engl. J. Med. 2011; 364(11): 1027–36.Grimwade D., Hills R.K., Moorman A.V., Walker H., Chatters S., Goldstone A.H., et al. Refnement of cytogenetic classifcation in acute myeloid leukemia: determination of prognostic signifcance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010; 116(3): 354–65.Grimwade D., Hills R.K., Moorman A.V., Walker H., Chatters S., Goldstone A.H., et al. Refnement of cytogenetic classifcation in acute myeloid leukemia: determination of prognostic signifcance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010; 116(3): 354–65.Oran B., Dolan M., Cao Q., Brunstein C., Warlick E., Weisdorf D. Monosomal karyotype provides better prognostic prediction after allogeneic stem cell transplantation in patients with acute myelogenous leukemia. Biol. Blood Marrow Transplant. 2011; 17(3): 356–64.Oran B., Dolan M., Cao Q., Brunstein C., Warlick E., Weisdorf D. Monosomal karyotype provides better prognostic prediction after allogeneic stem cell transplantation in patients with acute myelogenous leukemia. Biol. Blood Marrow Transplant. 2011; 17(3): 356–64.Yanada M., Kurosawa S., Yamaguchi T., Yamashita T., Moriuchi Y., Ago H., et al. Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission. Haematologica. 2012; 97(6): 915–8.Yanada M., Kurosawa S., Yamaguchi T., Yamashita T., Moriuchi Y., Ago H., et al. Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission. Haematologica. 2012; 97(6): 915–8.Middeke J.M., Beelen D., Stadler M., Gohring G., Schlegelberger B., Baurmann H., et al. Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and -5/5q-. Blood. 2012; 120(12): 2521–8.Middeke J.M., Beelen D., Stadler M., Gohring G., Schlegelberger B., Baurmann H., et al. Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and -5/5q-. Blood. 2012; 120(12): 2521–8.Breems D.A., van Putten W.L.J., Lowenberg B. The impact of abn(17p) and monosomy 25/del(5q) on the prognostic value of the monosomal karyotype in acute myeloid leukemia. Blood. 2013; 121(15): 3056–7.Breems D.A., van Putten W.L.J., Lowenberg B. The impact of abn(17p) and monosomy 25/del(5q) on the prognostic value of the monosomal karyotype in acute myeloid leukemia. Blood. 2013; 121(15): 3056–7.Yang Y.T., Hou H.A., Liu C.Y., Lin C.C., Chou W.C., Lee F.Y., et al. IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients. Am. J. Hematol. 2014; 89(9): E142–9.Yang Y.T., Hou H.A., Liu C.Y., Lin C.C., Chou W.C., Lee F.Y., et al. IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients. Am. J. Hematol. 2014; 89(9): E142–9.Cluzeau T., Mounier N., Karsenti J.M., Richez V., Legros L., Gastaud L., et al. Monosomal karyotype improves IPSS-R stratifcation in MDS and AML patients treated with azacitidine. Am. J. Hematol. 2013; 88(9): 780–3.Cluzeau T., Mounier N., Karsenti J.M., Richez V., Legros L., Gastaud L., et al. Monosomal karyotype improves IPSS-R stratifcation in MDS and AML patients treated with azacitidine. Am. J. Hematol. 2013; 88(9): 780–3.Pleyer L., Burgstaller S., Girschikofsky M., Linkesch W., Stauder R., Pfeilstocker M., et al. Azacitidine in 302 patients with WHO-defned acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group. Ann. Hematol. 2014; 93(11): 1825–38.Pleyer L., Burgstaller S., Girschikofsky M., Linkesch W., Stauder R., Pfeilstocker M., et al. Azacitidine in 302 patients with WHO-defned acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group. Ann. Hematol. 2014; 93(11): 1825–38.Della Porta M.G., Alessandrino E.P., Bacigalupo A., van Lint M.T., Malcovati L., Pascutto C., et al. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratifed according to the revised IPSS-R. Blood. 2014; 123(15): 2333–42.Della Porta M.G., Alessandrino E.P., Bacigalupo A., van Lint M.T., Malcovati L., Pascutto C., et al. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratifed according to the revised IPSS-R. Blood. 2014; 123(15): 2333–42.Itzykson R., Thґepot S., Eclache V., Quesnel B., Dreyfus F., Beyne-Rauzy O., et al. Prognostic signifcance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine. Leukemia. 2011; 25(7): 1207–9.Itzykson R., Thґepot S., Eclache V., Quesnel B., Dreyfus F., Beyne-Rauzy O., et al. Prognostic signifcance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine. Leukemia. 2011; 25(7): 1207–9.Valcaґrcel D., Adema V., Soleґ F., Ortega M., Nomdedeu B., Sanz G., et al. Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome. J. Clin. Oncol. 2013; 31(7): 916–22.Valcaґrcel D., Adema V., Soleґ F., Ortega M., Nomdedeu B., Sanz G., et al. Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome. J. Clin. Oncol. 2013; 31(7): 916–22.Sekeres M.A., Elson P., Kalaycio M.E., Advani A.S., Copelan E.A., Faderl S., et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood. 2009; 113(1): 28–36.Sekeres M.A., Elson P., Kalaycio M.E., Advani A.S., Copelan E.A., Faderl S., et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood. 2009; 113(1): 28–36.Bertoli S., Berard E., Huguet F., Huynh A., Tavitian S., Vergez F., et al. Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. Blood. 2013; 121(14): 2618–26.Bertoli S., Berard E., Huguet F., Huynh A., Tavitian S., Vergez F., et al. Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. Blood. 2013; 121(14): 2618–26.Luskin M.R., Lee J.W., Fernandez H.F., Lazarus H.M., Rowe J.M., Tallman M.S., et al. High dose daunorubicin improves survival in AML up to age 60, across all cytogenetic risk groups including patients with unfavorable cytogenetic risk, and FLT3-ITD mutant AML: updated analyses from Eastern Cooperative Oncology trial E1900. Blood. 2014; 124(21): Abstr. 373.Luskin M.R., Lee J.W., Fernandez H.F., Lazarus H.M., Rowe J.M., Tallman M.S., et al. High dose daunorubicin improves survival in AML up to age 60, across all cytogenetic risk groups including patients with unfavorable cytogenetic risk, and FLT3-ITD mutant AML: updated analyses from Eastern Cooperative Oncology trial E1900. Blood. 2014; 124(21): Abstr. 373.Burnett A.K., Russell N., Hills R.K., Kell J., Cavenagh J., Kjeldsen L., et al. A randomised comparison of daunorubicin 90mg/m2 vs 60mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2014; 124(21): Abstr. 7.Burnett A.K., Russell N., Hills R.K., Kell J., Cavenagh J., Kjeldsen L., et al. A randomised comparison of daunorubicin 90mg/m2 vs 60mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2014; 124(21): Abstr. 7.Bhella S.D., Atenafu E.G., Schuh A.C., Minden M.D., Schimmer A.D., Gupta V., et al. FLAG-IDA has signifcant activity as frontline induction or salvage therapy for patients with high risk and/or relapsed or refractory acute myeloid leukemia. Blood. 2014; 124(21): Abstr. 5285.Bhella S.D., Atenafu E.G., Schuh A.C., Minden M.D., Schimmer A.D., Gupta V., et al. FLAG-IDA has signifcant activity as frontline induction or salvage therapy for patients with high risk and/or relapsed or refractory acute myeloid leukemia. Blood. 2014; 124(21): Abstr. 5285.Wrzesień-Kus A., Robak T., Lech-Maranda E., Wierzbowska A., Dmoszynska A., Kowal M., et al. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia – a report of the Polish Adult Leukemia Group (PALG). Eur. J. Haematol. 2003; 71(3): 155–62.Wrzesień-Kus A., Robak T., Lech-Maranda E., Wierzbowska A., Dmoszynska A., Kowal M., et al. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia – a report of the Polish Adult Leukemia Group (PALG). Eur. J. Haematol. 2003; 71(3): 155–62.Seymour J.F., Dohner H., Butrym A., Wierzbowska A., Selleslag D., Jang J.H., et al. Azacitidine versus conventional care regimens in older patients with newly diagnosed acute myeloid leukemia (>30% bone marrow blasts) with morphologic dysplastic changes: a subgroup analysis of the AZA-AML-001 trial. Blood. 2014; 124(21): Abstr. 10.Seymour J.F., Dohner H., Butrym A., Wierzbowska A., Selleslag D., Jang J.H., et al. Azacitidine versus conventional care regimens in older patients with newly diagnosed acute myeloid leukemia (>30% bone marrow blasts) with morphologic dysplastic changes: a subgroup analysis of the AZA-AML-001 trial. Blood. 2014; 124(21): Abstr. 10.Zeidan A.M., Gore S.D., Komrokji R.S. Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go? Expert. Rev. Hematol. 2013; 6(3): 251–4.Zeidan A.M., Gore S.D., Komrokji R.S. Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go? Expert. Rev. Hematol. 2013; 6(3): 251–4.

The authors declare that there are no conflicts of interest present.